Herzer K, Müller S, Antoch G, Hilgard P
Department for Internal Medicine and Gastroenterology, Academic Teaching Hospital EVK, Germany.
Minerva Gastroenterol Dietol. 2011 Sep;57(3):287-98.
Compared with other malignant tumours, hepatocellular carcinoma (HCC) exhibits particular characteristics regarding its supplying vessels and tumour biology. If a potentially curative surgical approach, such as resection or liver transplantation, is due to technical or prognostical reasons no option, these characteristics are a fundamental prerequisite for the possibility to effectively treat this tumour by local ablation methods. Microsphere and particle technology with selective transport of tumoricidal substances or radiation represents a new generation of therapeutics in interventional oncology. With the intrahepatic application of radioactive microspheres via the hepatic artery (radioembolization) local ablation can be performed even of diffuse and multifocal liver tumours, which hitherto, could only be approached with systemic therapy. The present standard for radioembolization, is the use of yttrium-90 glass or resin microspheres. The indications, technique and current results of radioembolization with yttrium-90 microspheres for the treatment of HCC are discussed in this review.
与其他恶性肿瘤相比,肝细胞癌(HCC)在其供血血管和肿瘤生物学方面具有独特的特征。如果由于技术或预后原因无法选择潜在的根治性手术方法,如切除或肝移植,那么这些特征是通过局部消融方法有效治疗该肿瘤的可能性的基本前提。具有杀肿瘤物质或辐射选择性转运的微球和颗粒技术代表了介入肿瘤学中的新一代治疗方法。通过肝动脉进行放射性微球的肝内应用(放射性栓塞),即使是弥漫性和多灶性肝肿瘤也可以进行局部消融,而迄今为止,这些肿瘤只能采用全身治疗。目前放射性栓塞的标准是使用钇-90玻璃或树脂微球。本文综述了钇-90微球放射性栓塞治疗HCC的适应症、技术及当前结果。